GT Biopharma, Inc. is a clinical stage biopharmaceutical company developing novel immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein platforms. These platforms harness patients' natural killer (NK) cells to target cancer cells. Key pipeline candidates include GTB-3650 (AML/MDS), GTB-5550 (B7-H3+ solid tumors), and GTB-7550 (autoimmune disorders). The company conducts no manufacturing, relying on third-party CMOs.
expected 2026-12-25
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-02 | 2025-12-31 | 0001493152-26-008443 | EDGAR | 63K words |
| 2025-02-21 | 2024-12-31 | 0001493152-25-007908 | EDGAR | 56K words |
| 2024-03-26 | 2023-12-31 | 0001493152-24-011332 | EDGAR | 48K words |
| 2023-03-30 | 2022-12-31 | 0001493152-23-009812 | EDGAR | — |
| 2022-03-28 | 2021-12-31 | 0001493152-22-007883 | EDGAR | — |
| 2021-04-16 | 2020-12-31 | 0001654954-21-004295 | EDGAR | — |
| 2020-03-27 | 2019-12-31 | 0001654954-20-003380 | EDGAR | — |
| 2019-03-29 | 2018-12-31 | 0001654954-19-003697 | EDGAR | — |
| 2018-03-01 | 2017-12-31 | 0001654954-18-002054 | EDGAR | — |
| 2017-03-31 | 2016-12-31 | 0001654954-17-002919 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-14 | 2026-06-30 | 0001493152-26-037988 | EDGAR | 22K words |
| 2025-11-14 | 2025-09-30 | 0001493152-25-023400 | EDGAR | 26K words |
| 2025-08-14 | 2025-06-30 | 0001493152-25-011971 | EDGAR | 25K words |
| 2025-05-15 | 2025-03-31 | 0001641172-25-010790 | EDGAR | 19K words |
| 2024-11-14 | 2024-09-30 | 0001493152-24-045892 | EDGAR | 21K words |
| 2024-08-14 | 2024-06-30 | 0001493152-24-032143 | EDGAR | 21K words |
| 2024-05-15 | 2024-03-31 | 0001493152-24-019970 | EDGAR | 18K words |
| 2023-11-01 | 2023-09-30 | 0001493152-23-038957 | EDGAR | 20K words |
| 2023-08-07 | 2023-06-30 | 0001493152-23-026973 | EDGAR | 20K words |
| 2023-05-15 | 2023-03-31 | 0001493152-23-017492 | EDGAR | 17K words |
| 2022-10-31 | 2022-09-30 | 0001493152-22-030019 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001493152-22-022629 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-25 | 0001493152-26-044309 | EDGAR | 1K words |
| 2026-09-21 | 0001493152-26-043562 | EDGAR | 1K words |
| 2026-09-15 | 0001493152-26-042672 | EDGAR | 25K words |
| 2026-09-03 | 0001493152-26-041333 | EDGAR | 2K words |
| 2026-08-14 | 0001493152-26-038446 | EDGAR | 1K words |
| 2026-03-02 | 0001493152-26-008442 | EDGAR | 3K words |
| 2025-11-26 | 0001493152-25-025162 | EDGAR | 1K words |
| 2025-11-14 | 0001493152-25-022631 | EDGAR | 1K words |
| 2025-09-26 | 0001493152-25-015725 | EDGAR | 1K words |
| 2025-09-23 | 0001493152-25-014684 | EDGAR | 1K words |
406 total filings indexed. 374 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000109657 |
| Ticker | GTBP |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.gtbiopharma.com |
| Listed | 2021-02-11 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/GTBP (~200 tokens, structured JSON with cryptographic provenance)